Surface contamination from cytotoxic chemotherapy following preparation and administration

Journal of Pharmacy Practice and Research

Volumn 37, Issue 4, 2007, Pages 271-276

  Lee, Su Gil ^a   Tkaczuk, Michael ^a   Jankewicz, Ganyk ^a   Ambados, Fotios ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ARTICLE; CLEANING; CYTOTOXICITY; DRUG CONTAMINATION; DRUG PACKAGING; GLOVE; HAND WASHING; HEALTH CARE PERSONNEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; OCCUPATIONAL EXPOSURE; PROTECTIVE CLOTHING; RISK;

EID: 39449138151     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2007.tb00763.x     Document Type: Article

References (37)

1. National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati: NIOSH; 2004.
2. Laffon B, Teixeira JP, Silva S, Loureiro J, Torres J, Pásaro E, et al. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphism in DNA repair enzymes. Am J Ind Med 2005; 48: 128-36.
3. Ursini CL, Cavallo D, Colombi A, Giglio M, Marinaccio A, Iavicoli S. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Int Arch Occup Environ Health 2006, 80: 134-40.
4. Burgaz S, Karahalil B, Bayrak P, Taskin L, Youngaslan F, Bökesay I, et al. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphosites and exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999; 439: 97-104.
5. Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken D, Green E, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 2005; 11: 69-78.
6. Baker ES, Connor TH. Monitoring occupation exposure to cancer chemotherapy drugs. Am J Health Syst Pharm 1996; 53: 2713-23.
7. Pilger A, Köhler I, Stettner H. Long-term monitoring of sister chromide exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs. Int Arch Occup Environ Health 2000; 73: 442-8.
8. SHPA Committee of Specialty Practice in Oncology. SHPA standards of practice for the safe handling of cytotoxic drugs in pharmacy departments. J Pharm Pract Res 2005; 35: 44-52.
9. Milkovic-Kraus S, Kraus O, Krsnjavi H. Environmental effects on chromosomes in oncology and radiology department personnel. Prev Med 1992; 21: 498-502.
10. Anwar WA, Salama SI, Serafy MM. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis 1994; 9: 315-17.
11. Labuhn K, Valanis B, Schoeny R, Loveday K, Vollmer WM. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene and urine mutagenicity tests. Cancer Bursing 1998; 21: 79-89.
12. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos RP. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64: 105-12.
13. 2-alanine in urine. J Occup Med 1994; 36: 79-83.
14. Sessink PJ, Wittenhorst BC, Anzion RB, Bos RP. Exposure to pharmacy to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health 1997; 52: 240-4.
15. Connor TH, Sessink PJ, Harrison BR, Pretty JR, Peters BG, Alfaro RM, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm 2005; 62: 475-84.
16. Ziegler E, Mason HJ, Baxter PJ. Occupational exposure to cytotoxic drugs in the two UK oncology wards. Occup Environ Med 2002; 59: 608-12.
17. Mason HJ, Morton J, Garfitt SJ, Iqbal S, Jones K. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003; 47: 681-5.
18. Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri MJ, et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 2005; 49: 603-10.
19. Fransman W, Vermeulen R, Kromhout H. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 2005; 78: 403-12.
20. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals. Ann Occup Hyg 2004; 48: 237-44.
21. Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F, et al. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005; 49: 611-18.
22. Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49: 619-28.
23. Hedmer M, Georgiadi A, Bremberg R, Jönsson BA, Eksborg S. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 2005; 49: 629-37.
24. Sabatini L, Barbieri A, Tosi M, Violante FS. A new high-performance liquid chromatographic/electrospray ionisation tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom 2005; 40: 669-74.
25. Jackson CA, Wilson DA. World at work: hospital pharmacy clean-rooms. Occup Environ Med 2006; 63: 68-70.
26. Power LA. Demand clean vials. Am J Health Syst Pharm 2005; 62: 1.
27. Gilbar P. External contamination of cytotoxic drug vials [editorial]. J Pharm Pract Res 2005; 35: 264-5.
28. Workplace Health and Safety Queensland. Guide for handling cytotoxic drugs and related waste. Brisbane: Queensland Government; 2005.
29. Worksafe Victoria. Handling cytotoxic drugs in the workplace. Managing health & safety risks associated with handling cytotoxic drugs in the healthcare industry. Melbourne: Victorian WorkCover Authority; 2003.
30. Rossi S, Managing Editor. Australian Medicines Handbook. Adelaide: AMH; 2006. p. 529-30.
31. Hansel A, Categnaro M, Sportouch MH, De Méo M, Milhavet JC, Laget M, et al. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosphamide and melphalan. Int Arch Occup Environ Health 1997; 69: 109-14.
32. Johnson E, Janosik JE. Manufacturers' recommendations for handling spilled antineoplastic agents. Am J Hosp Pharm 1989; 46: 318-19.
33. Benvenuto JA, Connor TH, Monteith DK, Laidlaw JL, Adams SC, Matney TS, et al. Degradation and inactivation of antitumor drugs. J Pharm Sci 1993; 82: 988-91
34. Siderov J. Is the death knell for cytotoxic manufacturing in hospitals ringing [letter]? J Pharm Pract Res 2006; 36: 78.
35. American Society of Hospital Pharmacists Council on Professional Affairs. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm 2006; 63: 1172-91.
36. Cavallo D, Ursini CL, Pernoconi B, Di Francesco A, Giglio M, Rubino FM, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mulat Res 2005; 587: 45-51.
37. Jakab MG, Major J, Tompa A. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J Toxicol Environ Health A 2001; 62: 307-18.